[Treatment of acne with orally administered isotretinoin. Clinical study of 56 patients].
56 patients with nodulocystic acne, hidrosadenitis (2 cases) and steatocystoma multiplex (2 cases) were treated with oral isotretinoin. 52 patients cleared completely or were much improved without local treatment; 2 failures involved patients with steatocystoma, while 2 patients with ano-inguinal lesions were only improved. 19 patients received a dose of 0.5 mg/kg/day for six months; in 37 patients the dose was adapted to the initial response but did not exceed 1 mg/kg/day. Reversible elevated triglyceride concentration was observed in 5% of the patients. 18 patients were followed up and 4 (22%) presented moderate relapses.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D004305:Dose-Response Relationship, Drug; D004814:Epidermal Cyst / Q000188:drug therapy; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D015474:Isotretinoin; D008297:Male; D013543:Sweat Gland Diseases / Q000188:drug therapy; D014212:Tretinoin / Q000008:administration & dosage / Q000627:therapeutic use*
D014212:Tretinoin; D015474:Isotretinoin
Traitement de l'acné par l'isotrétinoïne par voie buccale. Etude clinique sur 56 patients.